PCS
NBRV

Personal CFO Solutions’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Personal CFO Solutions’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-146
Closed – – 414
2020
Q3 		$0 Sell
146
-12
-8% -$2.01K ﹤0.01% 356
2020
Q2 		$27K Hold
158
– – 0.01% 311
2020
Q1 		$23K Buy
158
+78
+98% +$23.9K 0.01% 271
2019
Q4 		$26K Buy
80
+16
+25% +$7.34K 0.01% 342
2019
Q3 		$37K Buy
+64
New +$36.1K 0.01% 284

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Personal CFO Solutions's NBRV Position: Q4 2020 in Review

Personal CFO Solutions sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q4 2020, closing a stake of 146 shares.

Personal CFO Solutions first reported a position in NBRV in Q3 2019 and held it in 5 quarters. The position peaked at $37K in Q3 2019. 33 funds tracked by Wall St. Rank hold NBRV as of Q4 2020.

  • Personal CFO Solutions reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q4 2020 after selling out during the quarter.
  • Personal CFO Solutions sold 146 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q4 2020.
  • Personal CFO Solutions first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2019 and held it in 5 quarters.
  • Personal CFO Solutions's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $37K in Q3 2019.
  • 33 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2020.

Based on Personal CFO Solutions's 13F filing for Q4 2020, filed 9 Feb 2021.